Adepthera has developed novel depot technology for sustained delivery of small molecules and peptides. We can provide customized depot formulation for branded and generic therapeutics on behalf of partner companies. The aqueous slow-release technology extends half-life and increases bioavailability without modifying the drug. The delivery excipient is “nonimmunogenic”, and can incorporate a variety of small molecules and peptides. Our lead assets include multiple therapeutic peptide depots that act on valid targets for the treatment of a variety of indications.
Based on the newly acquired platform technology and compelling data for our novel therapeutics, we are seeking partnership that leverages our delivery capability, and collaborators to co-develop our proprietary drug candidates.